Connect your AI

Allogene Therapeutics ALLO Total Assets

Total Assets at other companies

Bristol-Myers SquibbBMY

$86.48B-6.4%

Gilead SciencesGILD

$56.28B-0.3%

PrecigenPGEN

$138.63M+7.6%

CRISPR TherapeuticsCRSP

$2.73B+25.8%

Sana BiotechnologySANA

$373.59M-16.1%

CytomX TherapeuticsCTMX

$359.36M+265%

Other financials

Income statement

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Cash flow

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's total assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Allogene Therapeutics's total assets?: Allogene Therapeutics (ALLO) reported total assets of $395.96M in Q1 2026.
How has Allogene Therapeutics's total assets changed year-over-year?: Allogene Therapeutics's total assets decreased by 22.1% year-over-year, from $507.98M to $395.96M.
What is the long-term trend for Allogene Therapeutics's total assets?: Over 5 years (2020 to 2025), Allogene Therapeutics's total assets has grown at a -19.5% compound annual growth rate (CAGR), from $1.23B to $415.91M.
What does total assets mean?: The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.